ICU Medical Inc (ICUI) — 分析摘要
ICU Medical Inc(ICUI)的市值为3.94十亿美元,最近一年的营收同比增长了-6.3%。净利润率为0.0%。当前市盈率为85.0倍。
核心要点
- 营收同比变化-6.3%
- 净利润率0.0%
- 市盈率85.0倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,ICUI的营收增长为-6.3%,市盈率为85.0倍。
ICU Medical Inc (ICUI)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 0.5x — 盈利不足以覆盖利息支出
Debt/EBITDA 为 5.2x — 杠杆偏高
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
13,000
总部
SAN CLEMENTE, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。